BR112012027917A2 - anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano - Google Patents
anticorpos que apresentam reduzida imunogenicidade em um indivíduo humanoInfo
- Publication number
- BR112012027917A2 BR112012027917A2 BR112012027917A BR112012027917A BR112012027917A2 BR 112012027917 A2 BR112012027917 A2 BR 112012027917A2 BR 112012027917 A BR112012027917 A BR 112012027917A BR 112012027917 A BR112012027917 A BR 112012027917A BR 112012027917 A2 BR112012027917 A2 BR 112012027917A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- reduced immunogenicity
- human
- human subject
- human individual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano. a presente invenção está relacionada a anticorpos geneticamente modificados, os quais quando administrados a um indivíduo humano, apresentam um baixo nível de imunogenicidade no indivíduo humano. a presente invenção também está relacionada a métodos para a geração dos anticorpos. os anticorpos geneticamente modificados podem ser derivados de, por exemplo, anticorpos doadores não humanos (por exemplo, murinos) ou provenientes de anticorpos quiméricos ou humanizados que, quando administrados cronicamente a um ser humanom são conhecidos a, serem previsivos a, ou apresentarem expectativa para, eliciar uma resposta antianticorpo neutralizante no indivíduo humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33026110P | 2010-04-30 | 2010-04-30 | |
| PCT/US2011/034598 WO2011137362A1 (en) | 2010-04-30 | 2011-04-29 | Antibodies having reduced immunogenicity in a human |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012027917A2 true BR112012027917A2 (pt) | 2017-11-28 |
Family
ID=44861933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012027917A BR112012027917A2 (pt) | 2010-04-30 | 2011-04-29 | anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140206849A1 (pt) |
| EP (1) | EP2563812A4 (pt) |
| JP (1) | JP2013531476A (pt) |
| KR (1) | KR20130098161A (pt) |
| CN (2) | CN104402997A (pt) |
| BR (1) | BR112012027917A2 (pt) |
| CA (1) | CA2798120A1 (pt) |
| CO (1) | CO6660464A2 (pt) |
| EA (1) | EA201291133A1 (pt) |
| IL (1) | IL222691A0 (pt) |
| MX (1) | MX2012012689A (pt) |
| SG (1) | SG185107A1 (pt) |
| WO (1) | WO2011137362A1 (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| HUE029635T2 (en) | 2007-09-26 | 2017-03-28 | Chugai Pharmaceutical Co Ltd | A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR |
| DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
| WO2011137395A1 (en) | 2010-04-30 | 2011-11-03 | Rother Russell P | Anti-c5a antibodies and methods for using the antibodies |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| EP3196214B1 (en) | 2012-02-15 | 2019-07-31 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| PL2814842T3 (pl) | 2012-02-15 | 2018-12-31 | Novo Nordisk A/S | Przeciwciała wiążące białko 1 rozpoznające peptydoglikan |
| GB201220242D0 (en) * | 2012-11-09 | 2012-12-26 | Fusion Antibodies Ltd | Antibody |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN113943366A (zh) * | 2013-06-26 | 2022-01-18 | 努玛医疗技术有限公司 | 新型抗体框架 |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| RS65136B1 (sr) | 2014-07-17 | 2024-02-29 | Novo Nordisk As | Mutageza usmerena na lokaciju trem-1 antitela za smanjenje viskoziteta |
| ES2719876T3 (es) | 2014-10-15 | 2019-07-16 | Alexion Pharma Inc | Métodos para replicar un cultivo celular de producción de eculizumab a gran escala |
| US9908932B2 (en) | 2014-10-15 | 2018-03-06 | Alexion Pharmaceuticals, Inc. | Methods of shifting an isoelectric profile of a protein product and uses thereof |
| EP3699198A1 (en) | 2014-11-17 | 2020-08-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
| PL3233921T3 (pl) | 2014-12-19 | 2022-01-10 | Chugai Seiyaku Kabushiki Kaisha | Przeciwciała anty-c5 i sposoby ich stosowania |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CA3069756A1 (en) | 2017-07-27 | 2019-01-31 | Alexion Pharmaceuticals, Inc. | High concentration anti-c5 antibody formulations |
| AU2019248547A1 (en) | 2018-04-02 | 2020-09-10 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
| JP2021535142A (ja) | 2018-08-31 | 2021-12-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Ｃｄ３／ｃ２０二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略 |
| WO2021005607A1 (en) * | 2019-07-09 | 2021-01-14 | National Institute For Biotechnology In The Negev Ltd. | Antibodies with reduced immunogenicity |
| CN112210005B (zh) * | 2019-07-11 | 2024-03-26 | 京天成生物技术(北京)有限公司 | 低免疫原性低adcc/cdc功能的抗c5人源化单抗及其应用 |
| WO2022035888A2 (en) * | 2020-08-10 | 2022-02-17 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Sars-cov-2-neutralizing antibodies, biomarkers to predict protection from re-infection, and high efficiency antibody screening methods |
| US20240141061A1 (en) | 2021-01-12 | 2024-05-02 | Sg Medical Inc | Novel antibody against cd55 and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| WO2006117910A1 (ja) * | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| EP3381445B1 (en) * | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
-
2011
- 2011-04-29 WO PCT/US2011/034598 patent/WO2011137362A1/en active Application Filing
- 2011-04-29 EA EA201291133A patent/EA201291133A1/ru unknown
- 2011-04-29 JP JP2013508286A patent/JP2013531476A/ja not_active Withdrawn
- 2011-04-29 US US13/695,250 patent/US20140206849A1/en not_active Abandoned
- 2011-04-29 CA CA2798120A patent/CA2798120A1/en not_active Abandoned
- 2011-04-29 CN CN201410537722.0A patent/CN104402997A/zh active Pending
- 2011-04-29 CN CN2011800316723A patent/CN103108885A/zh active Pending
- 2011-04-29 EP EP11775642.9A patent/EP2563812A4/en not_active Withdrawn
- 2011-04-29 KR KR1020127031101A patent/KR20130098161A/ko not_active Application Discontinuation
- 2011-04-29 MX MX2012012689A patent/MX2012012689A/es not_active Application Discontinuation
- 2011-04-29 SG SG2012080404A patent/SG185107A1/en unknown
- 2011-04-29 BR BR112012027917A patent/BR112012027917A2/pt not_active IP Right Cessation
-
2012
- 2012-10-25 IL IL222691A patent/IL222691A0/en unknown
- 2012-11-29 CO CO12217151A patent/CO6660464A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140206849A1 (en) | 2014-07-24 |
| MX2012012689A (es) | 2013-12-16 |
| IL222691A0 (en) | 2012-12-31 |
| EA201291133A1 (ru) | 2013-04-30 |
| EP2563812A1 (en) | 2013-03-06 |
| CA2798120A1 (en) | 2011-11-03 |
| JP2013531476A (ja) | 2013-08-08 |
| WO2011137362A1 (en) | 2011-11-03 |
| SG185107A1 (en) | 2012-12-28 |
| CN103108885A (zh) | 2013-05-15 |
| CN104402997A (zh) | 2015-03-11 |
| KR20130098161A (ko) | 2013-09-04 |
| EP2563812A4 (en) | 2016-01-13 |
| CO6660464A2 (es) | 2013-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012027917A2 (pt) | anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano | |
| CY1121869T1 (el) | Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας | |
| CY1122700T1 (el) | Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (μηc) ii | |
| PH12018501548A1 (en) | Bispecific t cell engaging antibody constructs | |
| BR112017001183A2 (pt) | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
| WO2015112626A8 (en) | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules | |
| AR104809A1 (es) | Anticuerpos anti-cd40 y usos de los mismos | |
| BR112017007003A2 (pt) | método para modulação de atividade de células imunes induzidas por car | |
| BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
| BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
| BR112017003505A2 (pt) | anticorpos e receptores de antígeno quiméricos específicos para cd19 | |
| EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
| MX2021015971A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. | |
| BR112017005390A2 (pt) | células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva | |
| BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos | |
| BR112017008693A2 (pt) | célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição. | |
| EA201592269A1 (ru) | Способы и композиции для снижения иммуносупрессии опухолевыми клетками | |
| BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| BR112014026755A2 (pt) | anticorpos contra claudin 18.2 úteis no diagnóstico de câncer | |
| CR20140029A (es) | Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada | |
| EA201391608A1 (ru) | Наноносители, вырабатывающие иммунную толерантность, для антигенспецифического удаления т-эффекторных клеток | |
| PH12016501937A1 (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
| AR062268A1 (es) | Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |